Program
zilovertamab vedotin
Also written as “Zilovertamab vedotin” and “Zilovertamab Vedotin”.
Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Carcinoma, Transitional Cell · Burkitt Lymphoma · Triple Negative Breast Neoplasms, led by Merck.
Furthest: phase 3, since Nov 11, 202110 company-led studies, 7 open or runningNext primary completion: Sep 24, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 107 open or running | phase 3since Nov 11, 2021 | Feb 4, 2019 | Sep 24, 2027phase 3 · NCT05139017 |
- Named in Merck’s own pipeline as
zilovertamab vedotin (MK-2140)
, phase 3, as of Nov 2, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 4, 2019First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT03833180 · 91 enrolled · United States
- Aug 4, 2020Phase 2 study in Triple Negative Breast NeoplasmsNCT04504916 · 102 enrolled · United States, Canada
- Nov 11, 2021Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT05139017 · 290 planned · United States, Argentina, Australia and more
- Nov 22, 2021Phase 2 study in RecurrenceNCT05144841 · 140 enrolled · United States, Canada, Chile and more
- Jun 1, 2022Phase 2 study in LymphomaNCT05406401 · 60 enrolled · Canada, Israel, Italy and more
- Jul 11, 2022Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05458297 · 189 enrolled · United States, Brazil, Canada and more
- Sep 28, 2022Phase 2 study in Carcinoma, Transitional CellNCT05562830 · 48 enrolled · United States, Australia, Canada and more
- Feb 1, 2024Phase 2 study in Burkitt LymphomaNCT06395103 · 90 planned · United States, Australia, Belgium and more
- Dec 2, 2024Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT06717347 · 1,046 planned · United States, Argentina, Australia and more
- Mar 20, 2025Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT06890884 · 594 planned · United States, Belgium, Germany and more
Ahead
- Sep 24, 2027Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT05139017
- Dec 13, 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT06890884
- Feb 26, 2029Primary completion: phase 2 study in Carcinoma, Transitional CellNCT05562830
- Mar 31, 2029Primary completion: phase 2 study in Burkitt LymphomaNCT06395103
TargetBeta
“An antibody-drug conjugate (ADC) composed of zilovertamab, a humanized, immunoglobulin G (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) conjugated, via a proteolytically cleavable linker, to the auristatin derivative an…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of zilovertamab, a humanized, immunoglobulin G (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) ”NCIt, by rule
Other programs on ROR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07rule | shanghai-epimab-biotherapeutics-co-ltd | phase 2 | 2 |
| TQB2101 | Sino Biopharmaceutical | phase 1 | 2 |
| Anti-ROR1 Antibody-drug Conjugate IM-1021rule | Immunome | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06890884Lymphoma, Large B-Cell, Diffuse · United States, Belgium, Germany and more | 2 | Recruiting | Dec 13, 2027 | 594 |
| NCT06717347Lymphoma, Large B-Cell, Diffuse · United States, Argentina, Australia and more | 3 | Recruiting | Jul 2, 2029 | 1,046 |
| NCT06395103Burkitt Lymphoma · United States, Australia, Belgium and more | 2 | Recruiting | Mar 31, 2029 | 90 |
| NCT05562830Carcinoma, Transitional Cell · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 26, 2029 | 48 |
| NCT05458297Leukemia, Lymphocytic, Chronic, B-Cell · United States, Brazil, Canada and more | 2 | Active, not recruiting | May 17, 2029 | 189 |
| NCT05406401Lymphoma · Canada, Israel, Italy and more | 2 | Active, not recruiting | Apr 26, 2029 | 60 |
| NCT05144841Recurrence · United States, Canada, Chile and more | 2 | Completed | Apr 21, 2026 | 140 |
| NCT05139017Lymphoma, Large B-Cell, Diffuse · United States, Argentina, Australia and more | 3 | Recruiting | Sep 24, 2027 | 290 |
| NCT04504916Triple Negative Breast Neoplasms · United States, Canada | 2 | Terminated | Jun 12, 2023 | 102 |
| NCT03833180Leukemia, Lymphocytic, Chronic, B-Cell · United States | 1 | Completed | Dec 18, 2023 | 91 |
How it is read
Names in the registry
- “Zilovertamab vedotin”, 9 entries
- “Zilovertamab Vedotin”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 studies
- Carcinoma, Transitional Cell, 1 study
- Burkitt Lymphoma, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.